Personalized Medicine: Optimizing Outcomes for Patients with CLL

Opinion
Video

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Zanabrutinib Remains Favorable Over Bendamustine/Rituximab in CLL/SLL

Zanabrutinib Remains Favorable Over Bendamustine/Rituximab in CLL/SLL

Tim Cortese
January 3rd 2025
Article

At a median follow-up of 61.2 months, zanabrutinib demonstrated superior PFS vs bendamustine and rituximab in patients with CLL and SLL.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

A Phase 1 Clinical Trial of NKTR-255 With CD19-22 CAR T-Cell Therapy for Refractory B-Cell Acute Lymphoblastic Leukemia

A Phase 1 Clinical Trial of NKTR-255 With CD19-22 CAR T-Cell Therapy for Refractory B-Cell Acute Lymphoblastic Leukemia

American Society for Transplantation and Cellular Therapy
December 24th 2024
Article

Researchers at Stanford University have conducted a phase 1 clinical trial evaluating the combination of a bispecific CAR T-cell therapy targeting CD19 and CD22 with NKTR-255.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

Darlene Dobkowski, MA
December 16th 2024
Article

Median duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.

Ponatinib-Related Toxicity Management in ALL/CML Improves Over Time

Jonah Feldman
December 14th 2024
Article

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.